Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestMortgage LoansNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - DoubtfulReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

WORK Medical Technology (WOK) Current Deferred Revenue (2023 - 2025)

WORK Medical Technology (WOK) posted Current Deferred Revenue of $402407.0 for Q3 2025, down 65.5% on a QoQ basis from $1.2 million in Q1 2025, and down 35.65% year-over-year from $625326.0 in Q3 2024.

WORK Medical Technology (WOK) has 3 years of Current Deferred Revenue data on file, last reported at $402407.0 in Q3 2025.

  • In Q3 2025, Current Deferred Revenue fell 35.65% year-over-year to $402407.0; the TTM figure through Sep 2025 stood at $402407.0 (down 35.65% YoY), while the FY2025 annual figure was $402407.0, down 35.65% from the prior year.
  • Current Deferred Revenue declined to $402407.0 in Q3 2025, from $1.2 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $1.2 million in Q1 2025 and bottomed at $402407.0 in Q3 2025.
  • A 3-year average of $742618.2 and a median of $700768.0 in 2023 frame the typical range for Current Deferred Revenue.
  • Annual changes were most pronounced in 2024 — Current Deferred Revenue slipped 19.44% — and 2025, when it slumped 35.65%.
  • Year by year, Current Deferred Revenue stood at $776210.0 in 2023, then dropped by 19.44% to $625326.0 in 2024, then slumped by 35.65% to $402407.0 in 2025.
  • The last three Current Deferred Revenue figures came in at $402407.0 (Q3 2025), $1.2 million (Q1 2025), and $625326.0 (Q3 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 WORK Medical Technology - - -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2025 402,407.00
Mar 31, 2025 1.17 Mn
Sep 30, 2024 625,326.00
Sep 30, 2023 776,210.00